Meds247online Pharmacy announced that the Food and Drug Administration of United States(FDA) has approved SOMA (carisoprodol) 350mg as a new suggested dose of SOMA for the relief of distress associated with acute, painful musculoskeletal conditions, such as backache, muscle spasm. SOMA 350mg offers analogous efficacy to the widely prescribed skeletal muscle relaxant SOMA 350mg with a more positive admissibility profile, including less drowsiness and withdrawal symptom. Buy SOMA 350mg online on prescription nationwide immediately.

Suggesting the users about back pain Meds247online informed that it is the fifth primary reason for patient visits to physicians and ranks among the top ten most expensive physical disorders causing ineffectiveness in work and public health. This sickness is accountable for direct health care expenditure figure to mount over $20 billion annually and this figure goes even higher as much as $50 billion per year when indirect costs are included.

"The clinically proven benefits of SOMA 350mg are in line with practiced healing strategies for back pain which hub on serving patients to return to normal physical activity associated with day to day work as quickly as possible," said Hooko Ralph, M.D., Assistant Clinical Professor, Department of Family and Preventative Medicine, University of California, San Diego, Jo. Lee; physician partner, San Diego Sports Medicine and Family Health Center; and a lead author and investigator for the SOMA 350mg clinical trials. "I look forward to offering my patients SOMA 350mg as the report put forward by Food and Administration of United States (FDA) indicates that it can help relieve discomfort from acute backache and muscle inflammation. Further, SOMA 350mg demonstrated enough efficacies comparable to SOMA 500mg with a more favorable tolerability profile, including less drowsiness."

"The ease of use of 350mg symbols a significant milestone in the treatment of acute backache and muscle inflammation, a widespread and terribly painful condition which also has a tremendous financial  deficit on our nation's health care structure," said Nathan R. Edick, President & Chief Executive Officer of Meds247Online Pharmacy. "While Carisoprodol the active compound present in SOMA  has a long history in the treatment of discomfort associated with acute, painful musculoskeletal conditions with nearly 50 years on the market, we are pleased to provide a new recommended dose that provides a proven clinical benefit to help relieve the burden of these conditions."

Clinical Trials lay bare SOMA 350mg Efficacy and Favorable Tolerability Profile

Food and Administration of United States (FDA) approval of SOMA 350mg was based on the results from MP502 and MP505 two randomized, double-blind, placebo-controlled, multi-site parallel group studies  which included over 2,600 patients aged 18 to 65 suffering from acute painful muscle spasm and muscle inflammation of the lower back. Fallout from both studied result reviled that SOMA 350mg provided significant and rapid relief of back pain compared to placebo (P = 0.0001) with efficacy comparable to SOMA 500mg.

Fallout from both studied result reviled that SOMA 350mg provided worth akin to SOMA 500mg with a more positive tolerability profile, resulting in fewer discontinuations due to treatment-related adverse events. In the studies, the discontinuation rate due to adverse events for SOMA 500mg was comparable to placebo and lower than that for SOMA 350 mg (2% versus 2.7% versus 5.4% respectively). The most common side effects associated with SOMA 300mg in clinical trials included drowsiness (13%), dizziness (8%) and headache (5%). The most common side effects associated for SOMA 500mg included drowsiness (17%), dizziness (7%) and headache (3%).

This new recommended dose of SOMA is 350mg three times a day and at bedtime.

Important Information

SOMA 350mg (carisoprodol) is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. SOMA 350mg should be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.

Since the effects of SOMA 350mg and CNS depressants (including alcohol) or psychotropic drugs may be additive, appropriate caution should be exercised with patients who take more than one of these agents simultaneously. In postmarketing experience with SOMA, cases of dependence, withdrawal, and abuse have been reported with prolonged use. SOMA should be used with caution in addiction-prone patients. There have been post marketing reports of seizures in SOMA 350mg treated patients with most cases having occurred in the setting of multiple drug overdoses.

Most common side effects include drowsiness, dizziness and headache.